Live
- BJP hijacked electoral machinery for securing victory in Maharashtra: Cong
- Guwahati to host Indian National Rally Sprint Championship on Sunday
- Priyanka will now be seen in Wayanad more often: Robert Vadra
- Cong won all 3 seats on basis of guarantees, development: Dy CM on K’taka bypolls
- Santosh Trophy: Odisha rout Chhattisgarh to make final rounds
- BJP hijacked electoral machinery for securing victory in Maharashtra: Cong
- Formula 1: Russell pips Sainz to take pole in Las Vegas GP
- India under Trump 2.0 could bolster its position in global supply chains
- People voted for ideology, rejected dynasty: Sudhanshu Trivedi on Maha victory
- AP, Telangana to receive rains for next three days as low pressure to turn depression
Lupin gets US FDA approval for Paliperidone Extended-Release Tablets
Pharma major Lupin
Pharma major Lupin on Thursday announced that it has received approval from the United States Food and Drug Administration (FDA) to market Paliperidone Extended-Release Tablets in the American market.
Pharma major Lupin on Thursday announced that it has received approval from the United States Food and Drug Administration (FDA) to market Paliperidone Extended-Release Tablets in the American market.
Paliperidone extended-release tablets are used to treat Schizophrenia.
The drug maker in a regulatory filing said, "It has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg, and 9 mg, to market a generic equivalent of Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Research and Development, LLC."
The product will be manufactured at Lupin's facility in Goa, India.
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S. (IQVIA MAT March 2022).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
